133 related articles for article (PubMed ID: 38318635)
21. Pharmacoeconomic analysis of antifungal therapy for primary treatment of invasive candidiasis caused by Candida albicans and non-albicans Candida species.
Ou HT; Lee TY; Chen YC; Charbonneau C
BMC Infect Dis; 2017 Jul; 17(1):481. PubMed ID: 28693479
[TBL] [Abstract][Full Text] [Related]
22. Epidemiology of candidemia and antifungal susceptibility in invasive Candida species in the Asia-Pacific region.
Wang H; Xu YC; Hsueh PR
Future Microbiol; 2016 Oct; 11():1461-1477. PubMed ID: 27750452
[TBL] [Abstract][Full Text] [Related]
23. The Inhibitory Effect of Human Beta-defensin-3 on
Inthanachai T; Thammahong A; Edwards SW; Virakul S; Kiatsurayanon C; Chiewchengchol D
Immunol Invest; 2021 Jan; 50(1):80-91. PubMed ID: 32316784
[No Abstract] [Full Text] [Related]
24. Caenorhabditis elegans as a Model System To Assess Candida glabrata,
Hernando-Ortiz A; Mateo E; Ortega-Riveros M; De-la-Pinta I; Quindós G; Eraso E
Antimicrob Agents Chemother; 2020 Sep; 64(10):. PubMed ID: 32718968
[TBL] [Abstract][Full Text] [Related]
25. The epidemiology of Candida glabrata and Candida albicans fungemia in immunocompromised patients with cancer.
Bodey GP; Mardani M; Hanna HA; Boktour M; Abbas J; Girgawy E; Hachem RY; Kontoyiannis DP; Raad II
Am J Med; 2002 Apr; 112(5):380-5. PubMed ID: 11904112
[TBL] [Abstract][Full Text] [Related]
26. Emergence of non-Candida albicans species: Epidemiology, phylogeny and fluconazole susceptibility profile.
Sadeghi G; Ebrahimi-Rad M; Mousavi SF; Shams-Ghahfarokhi M; Razzaghi-Abyaneh M
J Mycol Med; 2018 Mar; 28(1):51-58. PubMed ID: 29366545
[TBL] [Abstract][Full Text] [Related]
27. Candida and candidaemia. Susceptibility and epidemiology.
Arendrup MC
Dan Med J; 2013 Nov; 60(11):B4698. PubMed ID: 24192246
[TBL] [Abstract][Full Text] [Related]
28. Efficacy of micafungin in invasive candidiasis caused by common Candida species with special emphasis on non-albicans Candida species.
Cornely OA; Vazquez J; De Waele J; Betts R; Rotstein C; Nucci M; Pappas PG; Ullmann AJ
Mycoses; 2014 Feb; 57(2):79-89. PubMed ID: 23786573
[TBL] [Abstract][Full Text] [Related]
29. The presence of an FKS mutation rather than MIC is an independent risk factor for failure of echinocandin therapy among patients with invasive candidiasis due to Candida glabrata.
Shields RK; Nguyen MH; Press EG; Kwa AL; Cheng S; Du C; Clancy CJ
Antimicrob Agents Chemother; 2012 Sep; 56(9):4862-9. PubMed ID: 22751546
[TBL] [Abstract][Full Text] [Related]
30. Frequency of clinically isolated strains of oral Candida species at Kagoshima University Hospital, Japan, and their susceptibility to antifungal drugs in 2006-2007 and 2012-2013.
Kamikawa Y; Mori Y; Nagayama T; Fujisaki J; Hirabayashi D; Sakamoto R; Hamada T; Sugihara K
BMC Oral Health; 2014 Feb; 14():14. PubMed ID: 24552136
[TBL] [Abstract][Full Text] [Related]
31. Pharmacodynamics of a Long-Acting Echinocandin, CD101, in a Neutropenic Invasive-Candidiasis Murine Model Using an Extended-Interval Dosing Design.
Lepak AJ; Zhao M; VanScoy B; Ambrose PG; Andes DR
Antimicrob Agents Chemother; 2018 Feb; 62(2):. PubMed ID: 29203480
[TBL] [Abstract][Full Text] [Related]
32. Significantly Improved Pharmacokinetics Enhances
Zhao Y; Lee MH; Paderu P; Lee A; Jimenez-Ortigosa C; Park S; Mansbach RS; Shaw KJ; Perlin DS
Antimicrob Agents Chemother; 2018 Oct; 62(10):. PubMed ID: 30012766
[TBL] [Abstract][Full Text] [Related]
33. Candida glabrata - basic characteristics, virulence, treatment, and resistance.
Eliaš D; Gbelská Y
Epidemiol Mikrobiol Imunol; 2022; 71(2):118-134. PubMed ID: 35940866
[TBL] [Abstract][Full Text] [Related]
34. Hormones modulate Candida vaginal isolates biofilm formation and decrease their susceptibility to azoles and hydrogen peroxide.
Gonçalves B; Azevedo NM; Henriques M; Silva S
Med Mycol; 2020 Apr; 58(3):341-350. PubMed ID: 31254346
[TBL] [Abstract][Full Text] [Related]
35. Distribution and antifungal susceptibility pattern of
Bilal H; Shafiq M; Hou B; Islam R; Khan MN; Khan RU; Zeng Y
Virulence; 2022 Dec; 13(1):1573-1589. PubMed ID: 36120738
[TBL] [Abstract][Full Text] [Related]
36. Molecular typing and in vitro fluconazole susceptibility of Candida species isolated from diabetic and nondiabetic women with vulvovaginal candidiasis in India.
Lattif AA; Mukhopadhyay G; Banerjee U; Goswami R; Prasad R
J Microbiol Immunol Infect; 2011 Jun; 44(3):166-71. PubMed ID: 21524609
[TBL] [Abstract][Full Text] [Related]
37. Whole genome analysis of echinocandin non-susceptible Candida Glabrata clinical isolates: a multi-center study in China.
Li Y; Hou X; Li R; Liao K; Ma L; Wang X; Ji P; Kong H; Xia Y; Ding H; Kang W; Zhang G; Li J; Xiao M; Li Y; Xu Y
BMC Microbiol; 2023 Nov; 23(1):341. PubMed ID: 37974063
[TBL] [Abstract][Full Text] [Related]
38. Missense mutation in CgPDR1 regulator associated with azole-resistant Candida glabrata recovered from Thai oral candidiasis patients.
Tantivitayakul P; Lapirattanakul J; Kaypetch R; Muadcheingka T
J Glob Antimicrob Resist; 2019 Jun; 17():221-226. PubMed ID: 30658200
[TBL] [Abstract][Full Text] [Related]
39. Bayesian estimation of post-test probability of Candida glabrata fungemia by means of serum creatinine.
Leli C; Gotta F; Ferrara L; Scomparin E; Bona E; Ciriello MM; Rocchetti A
New Microbiol; 2022 Dec; 45(4):324-330. PubMed ID: 36538297
[TBL] [Abstract][Full Text] [Related]
40. Clinical perspectives on echinocandin resistance among Candida species.
Shields RK; Nguyen MH; Clancy CJ
Curr Opin Infect Dis; 2015 Dec; 28(6):514-22. PubMed ID: 26524326
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
